KN-044

重组人源化CTLA-4单域抗体Fc融合蛋白

Report date: 2022/01/14 13:23:58

Base Information

Drug NameKN-044
Drug Alias Name重组人源化CTLA-4单域抗体Fc融合蛋白注射液KN-044
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSuzhou Alphamab Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChangchun Intellicrown Pharmaceutical Co LtdSuzhou Alphamab Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A